We are live on
!
Find out more
Vir Biotechnology
208 hedge funds and large institutions have $652M invested in Vir Biotechnology in 2024 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 69 increasing their positions, 69 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
141% more call options, than puts
Call options by funds: $9.81M | Put options by funds: $4.07M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
45% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 29
6% more funds holding
Funds holding: 197 → 208 (+11)
0.35% more ownership
Funds ownership: 64.11% → 64.47% (+0.35%)
0% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 69
1% less capital invested
Capital invested by funds: $656M → $652M (-$4.23M)
Holders
208
Holders Change
+11
Holders Change %
+5.58%
% of All Funds
2.74%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
42
Increased
69
Reduced
69
Closed
29
Calls
$9.81M
Puts
$4.07M
Net Calls
+$5.74M
Net Calls Change
+$13.4M
Top Buyers
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$8.55M |
| 2 |
SCM
Sio Capital Management
New York
|
+$8.32M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$7.24M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$7.08M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.65M |
Top Sellers
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$17.8M |
| 2 |
JFG
Jefferies Financial Group
New York
|
-$8.13M |
| 3 |
State Street
Boston,
Massachusetts
|
-$4.34M |
| 4 |
D.E. Shaw & Co
New York
|
-$3.38M |
| 5 |
O
OrbiMed
New York
|
-$2.8M |
